About this policy
The comment period for the MolDX: Guardant360® Plasma-Based Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer (NSCLC) DL37366 began on 06/20/2018 and ended on 08/07/2018. Comments were received from the provider community. The notice period begins on 10/04/2018 and ends 11/18/2018. The LCD becomes final on 11/19/2018.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.